Cargando…
A price comparison of recently launched proprietary pharmaceuticals in the UK and the US
OBJECTIVE: To explore the relationship between prices charged by manufacturers of proprietary pharmaceuticals in the US and in the UK in recent years (2013–2016), expressed as a multiplier, and to detail to what extent this relationship differs for high-cost therapies used in smaller patient populat...
Autores principales: | Jørgensen, Jesper, Kefalas, Panos |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Co-Action Publishing
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5023951/ https://www.ncbi.nlm.nih.gov/pubmed/27695606 http://dx.doi.org/10.3402/jmahp.v4.32754 |
Ejemplares similares
-
Data collection infrastructure for patient outcomes in the UK – opportunities and challenges for cell and gene therapies launching
por: Jørgensen, Jesper, et al.
Publicado: (2019) -
Outcomes-based reimbursement for gene therapies in practice: the experience of recently launched CAR-T cell therapies in major European countries
por: Jørgensen, Jesper, et al.
Publicado: (2020) -
The potential price and access implications of the cost-utility and budget impact methodologies applied by NICE in England and ICER in the US for a novel gene therapy in Parkinson’s disease
por: Jørgensen, Jesper, et al.
Publicado: (2018) -
Upgrading the SACT dataset and EBMT registry to enable outcomes-based reimbursement in oncology in England: a gap analysis and top-level cost estimate
por: Jørgensen, Jesper, et al.
Publicado: (2019) -
Reimbursement of licensed cell and gene therapies across the major European healthcare markets
por: Jørgensen, Jesper, et al.
Publicado: (2015)